ASCO 2017 | Abiraterone: a step forward in the treatment of prostate cancer

Eleni Efstathiou, MD, PhD, from the The University of Texas MD Anderson Cancer Center, Houston, TX, talks to us about the advancement in treating prostate cancer with the androgen biosynthesis inhibitor, abiraterone, at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL. She notes the possibility of limiting the extent of androgen deprivation therapy from the classic 3 years to 1.5 years, as evaluated from the good quality of life data obtained from clinical trials involving the treatment of prostate cancer with abiraterone, and states that this is a big advancement in the treatment of cancer.